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Regulatory Jurisdiction: Genetically Engineered Plants  
After more than ten years of plant biotechnology research and extensive field 
evaluation at sites throughout the United States (Gasser and Fraley, 1989), 
the first of several improved crop products being developed are undergoing 
regulatory review prior to market introduction. Before these products were 
submitted for review, the various U.S. regulatory bodies had considerable in-
put and oversight into the research and development undertaken to verify 
the performance and safety of these products. Initial research in the labora-
tory was performed under the National Institutes of Health (NIH) Recombi-
nant DNA Guidelines (1976; 1982). Several years of field-testing were car-
ried out under the jurisdiction of the United States Department of Agricul-
ture (USDA), in conjunction with the U.S. Environmental Protection Agency 
(EPA) for pesticidal plants. Regulatory approvals may be required by all 
three regulatory agencies (USDA, EPA and FDA [ Food and Drug Administra-
tion] ) prior to marketing these products. Early in this regulatory process, 
the Office of Science and Technology Policy (OSTP) issued the “Coordinated 
Framework for Regulation of Biotechnology” (1986) which assigned appro-
priate regulatory oversight and responsibility for biotechnology to these fed-
eral agencies, (see discussion by MacKenzie, p. 47)
USDA regulates the movement and release of genetically engineered 
plants under the Plant Pest and Quarantine Act since many of these plants are 
generated using organisms or DNA sequences from organisms that are plant 
pests. The program is administered by the Animal and Plant Health Inspec-
tion Service (APHIS). APHIS will make a determination concerning the 
plant pest status of varieties derived via biotechnology prior to market intro-
duction. EPA regulates the safety of the plant pesticidal products (e.g., pro-
teins that provide insect or disease resistance) as active ingredients and the 
protein(s) used in the selection process for generating these plants (e.g., se-
lectable marker proteins) as inert ingredients. FDA oversees the food and 
feed safety of products derived from these plants.
During the past decade, as progress has been made in the production, 
testing and development of plant biotechnology products, regulations and 
safety assessment requirements have developed to assure the safety of these 
products. There has been significant progress in the past twelve months by 
each of the three regulatory agencies in providing guidance and requesting 
public feedback on how these products will be regulated. The USDA pub-
lished draft guidelines in June of 1992 (APHIS, 
1992a) for public comment. The final policy 
was published in March, 1993 (APHIS, 1993). 
EPA published their proposed policy on regu-
lating plant pesticides, under the Federal Insec-
ticide, Fungicide and Rodenticide Act (FIFRA), 
for public comment and sponsored a Science 
Advisory Panel discussion on December 18,
1992 to obtain public input on this proposed policy (EPA, 1992). Likewise, 
FDA published their proposed policy for regulating genetically engineered 
plants and plant products on May 29,1992 for public comment (FDA, 1992).
The first of the products produced by plant biotechnology, the Flavr 
Savr™ tomato by Calgene, Inc. (Sheedy et al., 1988), has been reviewed for 
plant pest status by the USDA (APHIS, 1992c) and is presently under review 
for food and feed safety by the FDA (Redenbaugh et al., 1992). A petition to 
the USDA has also been submitted for virus-resistant squash by the Upjohn 
Company (APHIS, 1992b). With over 500 field tests that have been per-
formed around the world to date (Huttner et al., 1992; Casper and 
Landsmann, 1992) many other products are being extensively evaluated for 
agronomic, environmental and consumer value. The food, feed and environ-
mental safety of each of these will be assessed prior to marketing. One of 
these, a potato improved to control a specific insect pest without the use of 
chemical pesticides, serves as a case study for how this safety assessment is 
being performed to assure product wholesomeness and safety, environmen-
tal soundness and to support public confidence in these products.
The food, feed and 
environmental safety of 
each of these will he 
assessed prior to 
marketing.
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COLORADO POTATO BEETLE RESISTANT POTATOES
Potato plants that control that crop’s most serious insect pest, the Colorado Po-
tato Beetle (CPB), are among the first products that Monsanto has developed 
and for which we are completing a safety assessment. We have worked for nearly 
10 years to develop and evaluate these potato plants, which resist CPB through 
the production of an insect control protein, found in nature, that selectively 
controls the beetle without affecting nontarget in-
sects, humans or animals. These plants were pro-
duced by inserting and expressing a gene from Ba-
cillus thuringiensis subsp. tenebrionis (B.t.t.) in the 
potato plant (Perlaket al., 1993) using Agrobacterium 
transformation (Newell et al., 1991). The CPB-re- 
sistant plants produce low levels of two new proteins, 
the B.t.t. protein for resistance to CPB and the 
neomycin phosphotransferase (NPTII) protein produced to enable the 
selection of cells expressing the B.t.t. protein in tissue culture. The B.t.t. pro-
tein produced in these potato plants is the same as one of the insecticidal pro-
teins contained in several microbial formulations that have been used safely and 
have been commercially available since 1988 (EPA, 1988).
CPB is the most damaging pest of the $2.3 billion U. S. potato crop (Casa- 
grande, 1987; National Potato Council, 1992) and economically important 
in the majority of the North American potato production regions. Loss of 
revenue in Michigan alone was estimated at more than $15 million in a state 
where potato production is valued at $70 million (Potato Growers of Michi-
gan, 1992; Olkowski et al., 1992). If untreated or poorly managed, the CPB 
can devastate potato production in some areas (Hare, 1980; Ferro et al.,
1983; Shields and Wyman, 1984). Current treatment of CPB primarily in-
volves the use of insecticides that are variably effective due to environmental 
factors and insect insensitivity, and significantly reduce field populations of 
beneficial insects which help control other potato pests. These pesticides are 
also expensive, with costs that can exceed $200 per acre per season (Ferro 
and Boiteau, 1992).
Field trials conducted in 1991 with CPB-resistant potatoes demonstrated 
effective control of feeding damage by all stages of the CPB. There were sig-
nificantly fewer immature larvae, adults and egg masses of CPB on the gene-
tically improved potatoes, compared to the control plants. Without insecti-
cide application, defoliation of the improved potato plants was less than, or 
equal to, control plants sprayed with insecticides on a regular schedule. In 
addition, agronomic evaluations consisting of plant vigor, growth habit char-
acteristics and general insect and disease susceptibility, have shown the CPB- 
resistant potatoes to be equivalent to the parental Russet Burbank potatoes. 
Field tests were expanded in 1992 with similar results.
CPB [Colorado Potato 
Beetle] is the most 
damaging pest of the 
$2.3 billion U.S. potato 
crop...
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These genetically improved potatoes offer several advantages to the 
grower, the consumer and the environment for controlling this devastating 
insect pest. The superior CPB control offered by the plants will enable grow-
ers to significantly reduce the amount of chemical insecticide now applied to 
their crop while maintaining comparable yields. Re-
ducing the amount of insecticide applied to potatoes 
will further aid the implementation of Integrated 
Pest Management (IPM) practices as beneficial in-
sect populations will be maintained, which can help 
reduce the other pests of potatoes not directly con-
trolled by the CPB-control protein. The B.t.t. pro-
tein also has been shown to be safe to nontarget spe-
cies, including humans (EPA, 1988) and thus pro-
vides an environmentally safe means to control 
CPB. In addition, CPB-resistant potatoes will ben-
efit both large and small growers as no additional 
labor, planning or machinery is required for adoption. Prior to market in-
troduction, the potato lines will continue to be evaluated for performance 
and to refine insect management programs. Efforts will focus on confirming 
CPB control across the potato growing regions and developing production 
systems that optimize the benefits of these improved potatoes.
As with other food crops improved through biotechnology, USDA, EPA 
and FDA exercise joint regulatory oversight for these genetically improved po-
tatoes. All field tests have been carried with the approval of the USDA. In Oc-
tober 1992, an Experimental Use Permit (EUP) was requested from the EPA. 
The EUP permit, approved in May, 1993, allows for more extensive field eval-
uation of CPB-resistant potato varieties to be performed on more than 10 
acres. Prior to commercialization, a USDA determination of the nonreg- 
ulated status and an EPA product registration will be obtained under the re-
spective policies described above. Likewise, appropriate consultations with 
and oversight by FDA will be conducted as described in the FDA policy.
SAFETY ASSESSMENT OF CPB-RESISTANT POTATOES
Monsanto’s policy for ensuring the safety of the CPB-resistant potatoes is 
consistent with the published policies of the three regulatory agencies and 
relies on two approaches. The first approach is to provide appropriate infor-
mation to establish that the CPB-resistant potatoes are “substantially equiva-
lent” to the Russet Burbank potatoes from which this variety was derived.
The term “substantial equivalence” refers to the concept that the genetically 
improved potatoes are comparable to the Russet Burbank potatoes in respect 
to composition, nutritional quality, yield, morphology and in other aspects 
that could impact the use, value, and the environmental, food and feed safety 
of this product. The only significant difference that has been observed be-
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tween the genetically improved potatoes and the Russet Burbank potatoes is 
that the CPB-resistant potatoes effectively control the insect pest by express-
ing two additional proteins (B.t.t. and NPTII). No other differences have 
been observed. The concept of “substantial equivalence” or “substantial 
similarity” has been used by FDA (1992) and other international organiza-
tions (Organization for Economic Co-operation and Development, 1992; 
International Food Biotechnology Council, 1990) in their recommended ap-
proaches for safety assessment. In essence, this is the way new plant varieties 
and plant products have traditionally been regulated. In addition to estab-
lishing the “substantial equivalence” of the CPB-resistant potatoes to the 
Russet Burbank potatoes, we will also provide data to confirm the environ-
mental, human and animal safety of the two newly expressed B.t.t. and 
NPTII proteins.
SUBSTANTIAL EQUIVALENCE OF CPB-RESISTANT POTATOES TO 
RUSSET BURBANK POTATOES
Information concerning the source(s) of the genes introduced, the methods used 
to produce the genetically improved potato plants, the molecular characteriza-
tion of DNA introduced into these plants, and characterization of the levels 
of the B.t.t. and NPTII proteins serves as a basis for characterizing the CPB- 
resistant plants. The important nutritional and natural products in potato are 
being determined for both the genetically improved and Russet Burbank pota-
toes to show that the composition of the potato tuber has not been altered dur-
ing the transformation and regeneration processes. Levels of the macronutri-
ents—protein, fat, carbohydrate, dietary fiber and ash—are being determined. 
The levels of the important vitamins—vitamin C, vitamin B6, thiamine, nia-
cin, folic acid and riboflavin—are being assessed. Levels of important miner-
als—calcium, copper, iron, iodine, magne-
sium, phosphorus, potassium, sodium and 
zinc—are being evaluated. The only class of 
important potato natural toxicants, the 
glycoalkaloids (solanine and chaconine), have 
been quantified and shown to be comparable 
in both the genetically improved and Russet 
Burbank potatoes. Raw potato tubers from both the CPB-resistant and Russet 
Burbank potatoes were fed, along with the regular rat diet, to rodents in a 28- 
day study to assess the palatability of these potatoes. No differences in consumption, 
growth rates, or observations during gross necropsy were observed during these 
studies. These data have confirmed that the CPB-resistant potatoes are com-
parable to the Russet Burbank potatoes in all aspects except for the ability to 
control the CPB pest due to the presence of minor amounts of B.t.t. and NPTII 
proteins.
...use of registered B.t.t. 
products offers no significant 
risks to human health or 
nontarget organisms.
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SAFETY OF THE Bt PROTEIN
The Bt gene used to produce CPB-resistant potato plants, designated 
cry Ilia, (Hofte and Whiteley, 1989) was isolated from DNA from Bacillus 
thuringienses subsp. tenebrionis (McPherson et al., 1988). The Bt gene en-
codes an insecticidal protein produced by these bacteria during sporulation. 
The protein is selectively active against coleopteran larvae. Upon ingestion 
by susceptible species, feeding is inhibited with disruption of the gut epithe-
lium and eventual death of the insect pest (Slaney et al., 1992). The amino 
acid sequence encoded by the gene inserted into potato plants produces a 
protein that is identical to that produced by Bt found in nature 
(McPherson et al., 1988).
Based on the available scientific data, EPA and other regulatory agencies 
worldwide have determined that use of registered Bt products offers no 
significant risks to human health or nontarget organisms (Shields and 
Wyman, 1984; EPA, 1991). In published reviews and the EPA documents, 
studies are referenced where large doses (5000 mg per kg) of Bt prepara-
tions were administered as single or multiple doses to different laboratory 
animals with no adverse effects. Avian and aquatic organisms have also been 
fed Bt preparations with no adverse effects. The preparations which were 
administered contained varying amounts of crystalline proteins from Bt, 
either as a mixture with spores or encapsulated in killed Pseudomonas 
fluorescent cells (EPA, 1991). While target insects are susceptible to oral 
doses of Bt proteins (pg per gram of body weight), there was no evidence 
of any toxic effects observed in nontarget laboratory mammals, including 
fish or birds given the equivalent of up to 106 pg of protein per gram of body 
weight. No deleterious effects were observed on nontarget insects at doses 
over 300- to 700—fold that needed to control the target insects (Macintosh et 
al., 1990). In addition to the predicted lack of receptors for the Bt protein, 
the absence of adverse effects in nontarget animals is further facilitated by 
the poor solubility and rapid degradation of Bt proteins in the acid envi-
ronment of the digestive system.
To confirm the safety of the Bt protein expressed in CPB-resistant po-
tatoes, we have obtained gram quantities of purified Bt protein by express-
ing this protein in microbial systems (E. coli). Limited expression of this 
protein prohibited the isolation of large quantities of this protein from the 
potato tubers or potato plant directly. Minor amounts of this protein, puri-
fied from the potato tuber and from microbes, were shown to be chemically 
and functionally equivalent. A series of commonly used analytical assays 
were used for this equivalence assessment. An acute gavage study was con-
ducted in mice to confirm the safety of the Bt protein. A dose, following 
EPA guidelines, was used that was equivalent to over 2.5 million-fold safety 
factor based on the average consumption of potato and the level of the Bt
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protein present in the tuber. No adverse effects were observed in terms of 
food consumption, weight gain, mortality or gross necropsy observations. 
Purified protein was also used in an in vitro digestion experiment which 
demonstrated that the Bt protein has an extremely short half-life (less 
than 20 seconds) under simulated gastric conditions (The United States 
Pharmacopeia, 1990). These studies confirm the safety of the Bt protein 
to humans and animals.
The specificity of the Bt protein to CPB was confirmed by host-range 
studies using the purified Bt protein. Five nontarget, beneficial insects 
(including honey bees, lacewings, ladybird beetles and a parasitic wasp) were 
also shown to be unaffected by doses of the purified Bt protein that are 
greater than 100 times the amount required to affect the CPB-target insect. 
These studies confirm the specificity of the Bt protein and the safety of 
this protein to nontarget insects. We are also performing studies to confirm 
the rapid degradation of the Bt protein in the soil after potato tubers are 
harvested.
SAFETY OF THE NPTII PROTEIN
The NPTII protein, and hence the gene encoding this protein, was used as a 
selectable marker to enable the identification of potato cells that contained 
the B.t.t. gene. The description and safety assessment of the NPTII protein 
has been discussed in detail in the FDA submission for an advisory opinion 
by Calgene (1990) and by recent articles by Flavell et al. (1992) and Nap et al. 
(1992). In addition to this information, we have performed similar equiva-
lence acute gavage and digestive fate studies as described for the Bt protein 
above, with similar results. No adverse effects were observed in the acute 
gavage study with greater than a 5 million-fold safety compared to projected 
consumption, and the half-life of the NPTII protein in the simulated diges-
tive fate study was also less than 20 seconds, confirming the mammalian 
safety of this protein.
SUMMARY
A variety of plant biotechnology products have been developed and exten-
sively tested under field conditions. Appropriate regulatory oversight has 
evolved, and continues to evolve, through the various stages of the develop-
ment of this technology. All three regulatory agencies in the U.S. issued ei-
ther draft or final policies during 1992 that outline their policies on regulat-
ing genetically engineered plants. Two plant products are currently being 
reviewed under these policies and several more are expected to follow closely 
behind. One of these is the CPB-resistant potatoes that is described in this 
report. We have described the approaches that we are using to assess the 
food, feed and environmental safety of this product as an example. The
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philosophy is based on the concept of “substantial equivalence.” The new 
potato variety, derived using plant biotechnology, is established to be com-
parable to traditionally bred potatoes by comparing nutritional quality, level 
of important natural products, and agronomic and environmental perfor-
mance. In addition, a direct safety assessment of the newly expressed proteins 
(Bt and NPTII, for the CPB-resistant potato) confirmed the safety of these 
components. These safety assessments have confirmed the food, feed and 
environmental safety of the CPB-resistant potatoes. Similar assessments are 
being performed for other plant varieties derived using plant biotechnology 
to assess the safety of these products.
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